## ARNOLD & PORTER LLP

202.942.5000 202.942.5999 Fax

555 Twelfth Street, NW Washington, DC 20004-1206

November 23, 2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Application No. 09/523,102

Filed: March 10, 2000

Title: Methods and Compositions for Treating and Preventing

Retinal Neovascularization

Applicant:

Erwin SI et al.

Atty. Docket: 13587.286

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

- 1. an Information Disclosure Statement;
- 2. a Form PTO-1449 including two references; and
- 3. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

Applicants do not believe any fees are due in conjunction with this filing. However, if any fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387 referencing matter number 13587.286. A duplicate copy of this letter is enclosed.

Respectfully submitted,

David R. Marsh (Reg. Attorney No. 41,408)

Joseph W. Ricigliano\* (Reg. Agent No. 48,511)

## **Enclosures**

<sup>\*</sup>Not admitted to the practice of law in the District of Columbia. Admitted to practice in Virginia and before the U.S. Patent and Trademark Office only.

ENT AND TRADEMARK OFFICE

In re Application of:

Erwin SI et al.

Art Unit:

1651

Appln. No.: 09/523,102

Examiner:

Sandra E. Saucier

Filed:

March 10, 2000

Confirmation No.:

4492

For:

Methods and Compositions for

Treating and Preventing Retinal

Neovascularization

Atty. Docket:

13587.286

## **Information Disclosure Statement**

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the references listed on the attached Form PTO-1449. Copies of the references are submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

## Certification and/or Fee

Because this Information Disclosure Statement is being submitted prior to issuance of the first action on the merits of the above-captioned application, no certification or fee is required.

Respectfully submitted,

David R. Marsh (Reg. Atty. No. 41,408)

Joseph W. Ricigliano\* (Reg. Agent No. 48,511)

Date: November 23, 2005

ARNOLD & PORTER LLP 555 Twelfth Street, N.W. Washington, D.C. 20004-1206 (202) 942-5000 telephone (202) 942-5999 facsimile

<sup>\*</sup>Not admitted to the practice of law in the District of Columbia. Admitted to practice in Virginia and before the U.S. Patent and Trademark Office only.

					ATTY. DOCKET NO	),	APPLICATION NO.			
FORM PTO-1449  INFORMATION DISCLOSURE SPATEMENT					13587.286		09/523,102			
					APPLICANTS					
<u>INF</u>	ORMATIC	N DISCLOSURE			Erwin SI et al.					
NON 5 3 5002 R					FILING DATE	GROUP				
\40/				March 10, 2000		1651				
U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		DOCUMENT NUMBER		ATE	NAME		CLASS	SUB- CLASS	FILING DATE	
	FA1									
	FB1									
	FC1									
	FD1									
	FE1									
FOREIGN PATENT DOCUMENTS										
EXAMINER		DOCUMENT						SUB-		
INITIAL		NUMBER	D.	ATE	COUNTRY		CLASS	CLASS	TRANSLATION Yes	
	FF1								No	
	FG1								Yes No	
	FH1								Yes No	
	FI1								Yes No	
	FJ1								Yes No	
	l		OTHE	R (Includin	g Author, Title, Date, Per	tinent Pages, etc.)				
	FK1 Raza et al., "Matrix Metalloproteinases: Pro- and Anti-Angiogenic Activities", J Investig Dermatol Symp Proc, 5(1):47-54 (2000) (abstract only).									
	FL1	Stack et al., "Application of N-Carboxyalkyl Peptides to the Inhibition and Affinity Purification of the Porcine Matrix Metalloproteinases Collagenase, Gelatinase, and Stromelysin", Arch Biochem Biophys, 297(2):393 (1992) (abstract only).								
	FM1									
									·	
	FN1									
	FOI									
	FP1									
EXAMINER							DATE CONSIDERED			
		eference considered			is in conformance with Monlicant.	IPEP 609. Draw line t	hrough citation	on if not in co	onformance and not	